Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Replimune Announces Pricing of Upsized Public Offering GlobeNewswire - Mon Nov 25, 10:55PM CST

REPL : 12.49 (+4.00%)
Replimune Group, Inc. Announces Proposed Public Offering of $125 Million in Common Stock and Pre-Funded Warrants Quiver Quantitative, Inc. - Mon Nov 25, 4:32PM CST

Replimune Group announced a proposed $125 million public stock offering, with an option for an additional $18.75 million.Quiver AI SummaryReplimune Group, Inc., a clinical stage biotechnology company specializing...

REPL : 12.49 (+4.00%)
Replimune Announces Proposed Public Offering GlobeNewswire - Mon Nov 25, 6:09AM CST

REPL : 12.49 (+4.00%)
Replimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat Stocktwits - Fri Nov 22, 2:42AM CST

Replimune’s lead asset RP1 is based on a proprietary new strain of Herpes simplex virus engineered to maximize tumor killing potency.

IBB : 132.73 (+1.16%)
REPL : 12.49 (+4.00%)
XBI : 91.28 (+1.64%)
Replimune Group, Inc. Submits Biologics License Application for RP1 in Combination with Nivolumab for Advanced Melanoma Treatment Quiver Quantitative, Inc. - Fri Nov 22, 1:20AM CST

Replimune submitted a BLA to the FDA for RP1 with nivolumab, receiving Breakthrough Therapy designation for melanoma treatment.Quiver AI SummaryReplimune Group, Inc. announced the submission of a biologics...

REPL : 12.49 (+4.00%)
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway GlobeNewswire - Thu Nov 21, 3:05PM CST

REPL : 12.49 (+4.00%)
Insider Sale: Chief Medical Officer of $REPL (REPL) Sells 7,246 Shares Quiver Quantitative, Inc. - Thu Nov 21, 6:56AM CST

Konstantinos Xynos, the Chief Medical Officer of $REPL ($REPL), sold 7,246 shares of the company on 11-18-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

REPL : 12.49 (+4.00%)
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Tue Nov 12, 7:00AM CST

REPL : 12.49 (+4.00%)
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) GlobeNewswire - Sat Nov 9, 12:00PM CST

REPL : 12.49 (+4.00%)
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Nov 8, 3:01PM CST

REPL : 12.49 (+4.00%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot